Trial Profile

A Phase 1 trial assessing safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the orally administered therapy GAL-101

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GAL 101 (Primary)
Indications Alzheimer's disease; Dry age-related macular degeneration; Glaucoma
Focus Adverse reactions
Sponsors Thea Open Innovation

12 Sep 2025 According to Galimedix Therapeutics media release, the full study results are expected to be presented at a future scientific conference.
12 Sep 2025 According to Galimedix Therapeutics media release, status changed from recruiting to completed.
06 May 2025 According to Galimedix Therapeutics media release, the company announced completion of the single ascending dose (SAD) part of the Phase 1 study. The company is on track to complete later this year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com